439 related articles for article (PubMed ID: 29319354)
1. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension.
Liu WH; Xu XH; Luo Q; Zhang HL; Wang Y; Xi QY; Zhao ZH; Liu ZH
Clin Exp Hypertens; 2018; 40(3):224-230. PubMed ID: 29319354
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.
Lee MH; Cho YS; Han YM
Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin prevents and reverses chronic pulmonary hypertension in newborn rats via pleiotropic inhibition of RhoA signaling.
Wong MJ; Kantores C; Ivanovska J; Jain A; Jankov RP
Am J Physiol Lung Cell Mol Physiol; 2016 Nov; 311(5):L985-L999. PubMed ID: 27694473
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.
Wang HM; Wang Y; Liu M; Bai Y; Zhang XH; Sun YX; Wang HL
Can J Physiol Pharmacol; 2012 Nov; 90(11):1506-15. PubMed ID: 23181278
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin Increases Fibulin-2 Expression in Human Coronary Artery Smooth Muscle Cells via RhoA/Rho-Kinase Signaling Pathway Inhibition.
Serra N; Rosales R; Masana L; Vallvé JC
PLoS One; 2015; 10(7):e0133875. PubMed ID: 26207907
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats.
Wu F; Yao W; Yang J; Zhang M; Xu Y; Hao Y; Yan L; Niu Y; Sun T; Yu J; Zhou R
Biomed Pharmacother; 2017 Nov; 95():1161-1168. PubMed ID: 28926926
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin ameliorates rat cerebrovascular remodeling during hypertension via inhibition of volume-regulated chloride channel.
Liu YJ; Wang XG; Tang YB; Chen JH; Lv XF; Zhou JG; Guan YY
Hypertension; 2010 Sep; 56(3):445-52. PubMed ID: 20644009
[TBL] [Abstract][Full Text] [Related]
8. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
[TBL] [Abstract][Full Text] [Related]
9. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells.
Li M; Li Z; Sun X
Eur J Pharmacol; 2008 Sep; 591(1-3):219-23. PubMed ID: 18619957
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway.
Song JX; Ren JY; Chen H
J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011
[TBL] [Abstract][Full Text] [Related]
11. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
Eberlein M; Heusinger-Ribeiro J; Goppelt-Struebe M
Br J Pharmacol; 2001 Aug; 133(7):1172-80. PubMed ID: 11487529
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of 18β-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway.
Zhang M; Chang Z; Zhang P; Jing Z; Yan L; Feng J; Hu Z; Xu Q; Zhou W; Ma P; Hao Y; Zhou R
Chem Biol Interact; 2019 Sep; 311():108749. PubMed ID: 31325423
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.
Peng H; Luo P; Li Y; Wang C; Liu X; Ye Z; Li C; Lou T
PLoS One; 2013; 8(11):e80009. PubMed ID: 24244596
[TBL] [Abstract][Full Text] [Related]
14. Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension.
Zhu L; Liu F; Hao Q; Feng T; Chen Z; Luo S; Xiao R; Sun M; Zhang T; Fan X; Zeng X; He J; Yuan P; Liu J; Ruiz M; Dupuis J; Hu Q
Circulation; 2021 May; 143(18):1775-1792. PubMed ID: 33660517
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
Jiang L; Zhou T; Liu H
Pharmazie; 2012 Jun; 67(6):547-52. PubMed ID: 22822545
[TBL] [Abstract][Full Text] [Related]
16. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Al-Haidari AA; Syk I; Thorlacius H
Biochem Biophys Res Commun; 2014 Mar; 446(1):68-72. PubMed ID: 24582560
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA.
Porter KE; Turner NA; O'Regan DJ; Balmforth AJ; Ball SG
Cardiovasc Res; 2004 Mar; 61(4):745-55. PubMed ID: 14985071
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway.
Zhang Z; Wang M; Xue SJ; Liu DH; Tang YB
Cardiovasc Drugs Ther; 2012 Feb; 26(1):31-40. PubMed ID: 22083280
[TBL] [Abstract][Full Text] [Related]
19. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
